MicroCapClub

NeurAxis, Inc. (NRXS): Growth-Stage Medtech

Mar 2, 2026
Brian Carrico, President and CEO of NeurAxis, leads a growth-stage medtech company developing neuromodulation therapies for chronic gastrointestinal disorders. He discusses the impact of a Category I CPT code and payer coverage milestones. Conversation covers pediatric focus, VA market entry, clinical trial plans, scaling operations, and reimbursement strategy.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Strong Academic Evidence Built The Commercial Foundation

  • NeurAxis is first-to-market with FDA de novo clearance and multiple pediatric indications, supported by 16 investigator-initiated publications.
  • Academic society buy-in and publications aided payer decisions and the CPT application.
INSIGHT

Category One CPT Code Is A Major Credibility Catalyst

  • A Category 1 CPT code cements a medical technology in healthcare and unlocks RVUs that motivate hospital physicians.
  • NeurAxis earned the code after meeting strict criteria: five independent papers and 300 trained providers, which drives payer credibility.
INSIGHT

Pediatric Focus With Parallel VA Expansion

  • NeurAxis currently targets pediatric disorders of gut-brain interaction and has FDA indications in children 8–21 while pursuing adult RCT data.
  • They prioritize pediatric rollout and VA expansion because pediatric coverage exists and the VA has an FSS contract for adults.
Get the Snipd Podcast app to discover more snips from this episode
Get the app